Literature DB >> 11863348

A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort.

A Peeters1, A A Mamun, F Willekens, L Bonneux.   

Abstract

AIMS The objective of this paper is to measure the potential burden of cardiovascular disease within the original Framingham Heart Study cohort by transforming its well-described epidemiological measures into time-based health policy measures, such as life years lost to or lived with the disease. METHODS AND RESULTS We constructed multi-state life tables of the Framingham Heart Study cohort to calculate dwelling times with a history of cardiovascular disease. Age-specific probabilities determined transitions from healthy through disease to death. For this synthetic cohort, from age 50 men (women) live on average 26 (32) years; 20 (26) free of cardiovascular disease. Allowing occupancy of more than one disease state, 50-year-old males (females) live 2 X 9 (1 X 2) years with a history of myocardial infarction, 0 X 93 (1 X 2) with a history of stroke, and 0 X 67 (0 X 93) with congestive heart failure. Having ever suffered acute myocardial infarction, stroke or congestive heart failure, life expectancy is reduced by 9 (13), 12 (15) or 16 (16) years, respectively in 60-year-old men (women). CONCLUSIONS Transforming occurrence probabilities into time-based health measures, the prevalence of cardiovascular disease is remarkable: from age 50, 20% of remaining life expectancy is lived with the disease. Such measures are integral to appropriate health planning and assessment of the potential population health value of various treatment and prevention strategies. Copyright 2001 The European Society of Cardiology.

Entities:  

Mesh:

Year:  2002        PMID: 11863348     DOI: 10.1053/euhj.2001.2838

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  33 in total

1.  Screening for coronary heart disease: cardiology through the oncology looking glass.

Authors:  D Douglas Miller; Leslee J Shaw
Journal:  J Nucl Cardiol       Date:  2005 Mar-Apr       Impact factor: 5.952

2.  Cost-effectiveness of clopidogrel.

Authors:  Christopher P Cannon
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.

Authors:  Niteesh K Choudhry; Amanda R Patrick; Elliott M Antman; Jerry Avorn; William H Shrank
Journal:  Circulation       Date:  2008-02-19       Impact factor: 29.690

4.  Medical demography and epidemiology: dizygotic twins.

Authors:  Luc Gustaaf Antoon Bonneux
Journal:  Eur J Epidemiol       Date:  2009-03-17       Impact factor: 8.082

Review 5.  [Secondary prevention with antiplatelet therapy in cardiac rehabilitation].

Authors:  Maria M Wanitschek; Hannes F Alber
Journal:  Wien Med Wochenschr       Date:  2017-01-13

6.  Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.

Authors:  Paul Kolm; Yong Yuan; Emir Veledar; Shamir R Mehta; Judith A O'Brien; William S Weintraub
Journal:  Can J Cardiol       Date:  2007-11       Impact factor: 5.223

7.  Lifetime risk and projected population prevalence of diabetes.

Authors:  D J Magliano; J E Shaw; S M Shortreed; W J Nusselder; D Liew; E L M Barr; P Z Zimmet; A Peeters
Journal:  Diabetologia       Date:  2008-09-23       Impact factor: 10.122

8.  Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial.

Authors:  Rober C Welsh; Luc Sauriol; Zugui Zhang; Paul Kolm; Willian S Weintraub; Pierre Theroux
Journal:  Can J Cardiol       Date:  2009-12       Impact factor: 5.223

Review 9.  Life with and without heart disease among women and men over 50.

Authors:  Eileen M Crimmins; Mark D Hayward; Hiroshi Ueda; Yasuhiko Saito; Jung Ki Kim
Journal:  J Women Aging       Date:  2008

10.  Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention.

Authors:  Bart M S Heeg; Ron J G Peters; Marc Botteman; Ben A van Hout
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.